Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Keryx Biopharmaceuticals Inc (NASDAQ:KERX)

5.43
Delayed Data
As of Jan 20
 -0.21 / -3.72%
Today’s Change
2.80
Today|||52-Week Range
7.80
-7.34%
Year-to-Date
No recent news for Keryx Biopharmaceuticals Inc.

Today’s Trading

Previous close5.64
Today’s open5.71
Day’s range5.41 - 5.71
Volume1,686,140
Average volume (3 months)1,496,537
Market cap$597.6M
Dividend yield--
Data as of 4:00pm ET, 01/20/2017

Growth & Valuation

Earnings growth (last year)+3.25%
Earnings growth (this year)-20.13%
Earnings growth (next 5 years)+30.00%
Revenue growth (last year)+26.37%
P/E ratioNM
Price/Sales38.35
Price/Book6.82

Competitors

 Today’s
change
Today’s
% change
VNDAVanda Pharmaceutical...-0.35-2.57%
ITCIIntra-Cellular Thera...-0.27-1.95%
RVNCRevance Therapeutics...-0.20-0.98%
CLLSCellectis SA-0.09-0.51%
Data as of 4:00pm ET, 01/20/2017

Financials

Next reporting dateMarch 14, 2017
EPS forecast (this quarter)-$0.24
Annual revenue (last year)$13.7M
Annual profit (last year)-$123.1M
Net profit margin-900.18%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
Gregory P. Madison
Chief Financial Officer
Scott A. Holmes
Corporate headquarters
Boston, Massachusetts

Forecasts


Search for Jobs